Strategic Investments and Adjusted Gross Margin Report

01 F2024 STRATEGIC HIGHLIGHTS Completed planting first seed-based production grow room resulting from strategic investment in US-based Phylos • Advanced the second tranche of US$2.75 million to Phylos for a total current investment of US$6.0 million in senior secured convertible loans due to early achievement of THCV concentration and aroma milestones for F1 seeds Completed first craft harvest resulting from the completed expansion of the Company's Lac-Supérieur facility • Product Development Collaboration with BAT moving rapidly toward product commercialization. PK study for nano-emulsion gummy technology complete and the Company is compiling and analyzing results to substantiate product claims regarding onset and half-life • Applied for EU-GMP certification of Moncton facility in November 2023 and awaiting audit • ⚫ Subsequent to Q1 F2024 announced shareholder approval and closing of first $41.5 million tranche of $124.6 million follow-on investment from BAT and creation of the Jupiter investment pool to increase Organigram's international footprint BAT A BETTER TOMORROW PHYLOS 76 BIOSCIENCE GREENTANK ORGANIGRAM

View entire presentation